Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke

Summary

The purpose of this study is to evaluate the safety and efficacy of autologous peripheral hematopoietic stem cell transplantation in ischemic stroke.

Conditions

• Stroke

Interventions

PROCEDURE

autologous hematopoiesis stem cell transplantation

Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.

DRUG

Aspirin

aspirin 100mg,qd,po(patients with no fibrillation atrial)

DRUG

Warfarin

warfarin 2\~6mg,qd,po(patients with fibrillation atrial);

DRUG

Atorvastatin

atorvastatin 20mg,qd,po

DRUG

Edaravone

edaravone 30mg,bid,ivgtt.

DRUG

Aspirin

aspirin 100mg,qd,po(patients with no fibrillation atrial)

DRUG

Warfarin

warfarin 2\~6mg,qd,po(patients with fibrillation atrial)

DRUG

Atorvastatin

atorvastatin 20mg,qd,po

DRUG

Edaravone

edaravone 30mg,bid,ivgtt

Sponsors & Collaborators

• Zhejiang University

  collaborator OTHER

• Zhejiang Hospital

  lead OTHER

Principal Investigators

• Yaguo Li, master · Zhejiang Hospital

• Yumiao Zhou, master · Zhejiang Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

40 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2012-01-31

Primary Completion

2012-12-31

Completion

2013-12-31

Countries

• China

Study Locations